Geographic Atrophy: Slowing the Progression - Rapid Response From New York

Overview

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by an educational grant from Apellis Pharmaceuticals.

Activity Description

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) and leads to progressive and irreversible loss of visual function. It is estimated to affect 5 million people globally. Patient burden is significant, and ophthalmic providers do not always recognize this burden and the significant negative impact it presents in the daily life of these patients. To date, there are no approved treatments to reverse, prevent, or reduce the rate of GA progression. However, several potential therapies, including those that target the complement cascade, are in clinical trials, and the anticipated approval of these therapies will revolutionize treatment of GA. New advances in technology hold promise in identifying and allowing for the monitoring of lesion growth. In this educational activity, expert faculty will review the most recent data regarding the role of complement dysfunction in GA; the newer technological advances that can identify, monitor, and predict geographic lesion growth; and the emerging novel therapies that may reduce lesion growth in GA secondary to AMD.

Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with geographic atrophy.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Examine the use of newer technological advances to identify, monitor, and predict geographic lesion growth.
• Assess the latest evidence regarding novel emerging therapies that may reduce lesion growth in geographic atrophy secondary to age-related macular degeneration.

Activity Chair

Rishi P. Singh, MD
Staff Physician and President
Cleveland Clinic Martin Hospitals
Stuart, FL
Professor of Ophthalmology, Lerner College of Medicine, Case Western Reserve University
Cleveland, OH

Faculty

Caroline R. Baumal, MD, FASRS
Professor of Ophthalmology
Tufts Medicine
New England Eye Center
Boston, MA

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant financial relationship(s)

Caroline R. Baumal, MD, FASRS
Consultant: Genentech, Novartis, Ora, Regeneron, Zeiss

Rishi P. Singh, MD
Consultant: Apellis, AsclepiX, Genentech, Gyroscope, Iveric, Novartis, Regeneron

Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com